Evaluation of Myostatin Protein in Serum of Cardiac Patients

Ahmed Allawi Dhahir; Othman R Al Samarraı

doi:10.17776/csj.1572785

Evaluation of Myostatin Protein in Serum of Cardiac Patients

Abstract

In order to assess the significance of myostatin protein with some biochemical parameters in the blood serum of myocardial infarction and atherosclerosis patients. The study included 60 samples of heart patients (30 samples of myocardial infarction patients and 30 samples of patients with atherosclerosis) whose ages ranged from 35 to 65 years, in addition to 30 samples of healthy people of the same age group. Results revealed a marked rise in the level of myostatin protein in the myocardial infarction and atherosclerosis patients in comparison to healthy group, and rise in troponin protein in myocardial infarction patients. According to the findings, total cholesterol, triglycerides, low-density lipoproteins, and very-low-density lipoproteins were all significantly higher in the two patients groups than in healthy group, whereas high-density lipoprotein levels were significantly lower in both patients groups. The results indicated that calcium level had significantly decreased in myocardial infarction patients, but no change in phosphate level between groups. The findings revealed a significantly lower of glutathione and a significantly higher of malondialdehyde in the two patients groups as compared to the healthy group. In conclusion, the obtained data were directly aligned with the study hypothesis, showing significant elevation of myostatin and associated biochemical changes relevant to the pathophysiology of myocardial infarction and atherosclerosis, thus supporting the study objective. Results suggest myostatin as a potential supplementary biomarker and highlight useful biochemical alterations for patient assessment; however, lack of established diagnostic cut-offs, limited routine availability of myostatin testing, and small sample size may limit immediate clinical application.

Keywords

References

[1] Bachmann J. M., Willis B. L., Ayers C. R., Khera A., Berry J. D., Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study, Circulation, 125(25) (2012) 3092-3098.
[2] Aiello D., Patel K., Lasagna E., The myostatin gene: an overview of mechanisms of action and its relevance to livestock animals, Anim. Genet., 49(6) (2018) 505-519.
[3] Liu Y., Xu J., Wu M., Xu Y., Li M., Sun D., Yang X., Circulating myostatin is associated with insulin resistance in patients with type 2 diabetes mellitus, J. Diabetes Res., 2021 (2021) 5579273.
[4] Zhang C., McFarlane C., Lokireddy S., Bonala S., Ge X., Masuda S., Sharma M., Myostatin-deficient mice exhibit reduced insulin resistance through activating AMP-activated protein kinase, Diabetologia, 63(3) (2020) 580-593.
[5] Zhou Y., Hellberg M., Svensson P., Höglund P., Clyne N., Jacobson S. H., Association between circulating myostatin, body composition and muscle strength in patients with chronic kidney disease, Nephrol. Dial. Transplant., 34(3) (2019) 514-520.
[6] Camporez J. P., Petersen M. C., Abudukadier A., Moreira G. V., Jurczak M. J., Friedman G., Shulman G. I., Role of skeletal muscle myostatin in cancer cachexia, J. Clin. Invest., 130(4) (2020) 1704-1716.
[7] Morissette M. R., Cook S. A., Foo S., McKoy G., Ashida N., Novikov M., Rosenthal N., Myostatin regulates cardiomyocyte growth through modulation of Akt signaling, J. Biol. Chem., 291(4) (2016) 1745-1754.
[8] Biesemann N., Mendler L., Wietelmann A., Hermann S., Schäfers M., Krüger M., Bisping E., Myostatin regulates energy homeostasis in the heart and prevents heart failure, Circ. Res., 115(3) (2014) 296-310.

[9] Shah J., Walker’s A., Quantitative determination of MDA, Biochem. Biophys Acta, 11 (1989) 207-11.
[10] Sedlak J., Lindsay R. H., Analytical biochemistry, (1968) 192. cited by Al-Zamely O. M., Al-Nimer M. S., Muslih R. K., Detection the level of peroxynitrite and related with antioxidants status in the serum of patient with acute, (2001).
[11] Kesik V., Honca T., Gulgun M., Uysal B., Kurt Y. G., Cayci T., Korkmazer N., Myostatin as a marker for doxorubicin induced cardiac damage, Ann. Clin. Lab. Sci., 46 (2016) 26-31.
[12] Zamora E., Simó R., Lupón J., Galán A., Urrutia A., González B., Valle V., Serum myostatin levels in chronic heart failure, Revista Española de Cardiología (English Edition), 63(8) (2010) 992-996.
[13] Al-Duhaimi R., E Al-Gazalyally M., Haidar H. A., A study of high sensitivity c-reactive protein, fibrinogen, troponin I and lipid profile in patients with acute myocardial infarction, JKU, 8(1) (2012) 145-151.
[14] Sandoval Y., Bielinski S. J., Daniels L. B., Blaha M. J., Michos E. D., DeFilippis A. P., Jaffe A. S., Atherosclerotic cardiovascular disease risk stratification based on measurements of troponin and coronary artery calcium, J. Am. Coll. Cardiol., 76(4) (2020) 357-370.
[15] Solecki K., Dupuy A. M., Kuster N., Leclercq F., Gervasoni R., Macia J. C., Roubille F., Kinetics of high-sensitivity cardiac troponin T or troponin I compared to creatine kinase in patients with revascularized acute myocardial infarction, Clin. Chem. Lab. Med., 53(5) (2015) 707-714.
[16] Nadir T. M., Alsamarai A. T. S., Evaluation of correlation between serum and salivary fibronectin in myocardial infarction patients in Samarra city/Iraq, Samarra J. Pure. Appl. Sci., 3(1) (2021) 46-55.
[17] Al–Zubaidi A. M. A. H., Al-samarrai A. H. M., Estimation of spexin and resistin hormones and some biochemical parameters in males with heart disease in Samarra City-Iraq, Samarra J. Pure Appl. Sci., 3(2) (2021) 34-44.
[18] Obaidi O. R. K. A., Samarrai A. H. M. A., Samarrai S. S. M. A., Measuring the concentration of apolipoprotein B with some biochemical indicators and its relationship to high blood pressure in patients in the city of Samarra, Samarra J. Pure Appl. Sci., 2(4) (2020) 12-18.
[19] Kulsoom B., Hasnain S. N., Association of serum C-reactive protein and LDL: HDL with myocardial infarction, J. Pak. Med. Assoc., 56(7) (2006) 318.
[20] Mohammed Jaber S. K., Fahd Wahid I., Rashid Al Samarrai O., Evaluation of the effectiveness of the enzyme monoamine oxidase with some biochemical variants in patients with atherosclerosis, Samarra J. Pure Appl. Sci., 6(3) (2024) 14–22.
[21] Zrari S. A., Mohammed S. K., Diagnostic efficiency of serum creatine kinase and troponin I in patients with suspected acute myocardial infarction, TJS, 14(4) (2016) 314-319.
[22] Rasmussen K. L., Tybjærg-Hansen A., Nordestgaard B. G., Frikke-Schmidt R., Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population, Atherosclerosis, 246 (2016) 63-70.
[23] Yang T. C., Chen Y. J., Chang S. F., Chen C. H., Chang P. Y., Lu S. C., Malondialdehyde mediates oxidized LDL-induced coronary toxicity through the Akt-FGF2 pathway via DNA methylation, J. Biomed. Sci., 21 (2014) 1-12.
[24] Karalis D. G., Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease, Mayo Clinic Proceedings, 84(4) (2009) 345-352.
[25] Shirafkan A., Marjani A., Zaker F., Serum lipid profiles in acute myocardial infarction patients in Gorgan, Biomed. Res., 23(1) (2012) 119-124.
[26] Kurabayashi M., Role of calcium and phosphate in atherosclerosis and vascular calcification, Clin. Calcium., 23 (2013) 489–496.
[27] Muppidi V., Meegada S. R., Rehman A., Secondary hyperparathyroidism, (2020).
[28] Arjan A. R., The effect of Age & Sex on some serum electrolytes levels in patients with cardiovascular disease, JKU, 7(1) (2009).
[29] Ramadesikan V. K., Serum phosphate in acute myocardial infarction, Indian J. Physiol. Pharmacol., 44(2) (2000) 225-228.
[30] Kathyaini R., Gayatri S., Suleman D., A Study on Malondialdehyde as an Oxidative Stress Marker in Patients with Myocardial Infarction at a Tertiary Care Centre, N.J.L.M., 6(4) (2017) 13–16.
[31] Manita D., Yoshida H., Hirowatari Y., Cholesterol Levels of Six Fractionated Serum Lipoproteins and Its Relevance to Coronary Heart Disease Risk Scores, J. Atheroscler. Thromb., 24 (2017) 928–39.
[32] Jiang F., Xu X. R., Li W. M., Xia K., Wang L. F., Yang X. C., Monotropein alleviates H2O2-induced inflammation, oxidative stress and apoptosis via NF-κB/AP-1 signaling, Mol. Med. Rep., 22(6) (2020) 4828-4836.
[33] Kathyaini R., Gayatri S., Suleman D., A Study on Malondialdehyde as an Oxidative Stress Marker in Patients with Myocardial Infarction at a Tertiary Care Centre, N.J.L.M., 6(4) (2017) 13–16.

Details

Primary Language

English

Subjects

Analytical Biochemistry

Journal Section

Research Article

Authors

Ahmed Allawi Dhahir
0009-0008-9662-848X
Iraq

Othman R Al Samarraı ^*
0000-0002-1487-4054
Iraq

Publication Date

December 30, 2025

Submission Date

October 23, 2024

Acceptance Date

November 26, 2025

Published in Issue

Year 2025 Volume: 46 Number: 4

DOI

https://doi.org/10.17776/csj.1572785

IZ

https://izlik.org/JA75UC65YY

Cite

RIS / Bibtex

APA

Dhahir, A. A., & Al Samarraı, O. R. (2025). Evaluation of Myostatin Protein in Serum of Cardiac Patients. Cumhuriyet Science Journal, 46(4), 715-719. https://doi.org/10.17776/csj.1572785